Drugs in Dev. Endocrinology
Phase III
United Kingdom 
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eneboparatide Meets Primary Endpoint in CALYPSO Phase 3 for Hypoparathyroidism
Details : AZP-3601 (neboparatide) is a peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Eton Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.
Product Name : Alkindi Sprinkle
Product Type : Steroid
Upfront Cash : $3.5 million
March 27, 2020
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Eton Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Reset All
